Photocure ASA

Environmental & Social Information • Aug 29, 2016

Photocure Hosts Bladder Cancer Key Opinion Leader Breakfast in New York City

Photocure Hosts Bladder Cancer Key Opinion Leader Breakfast in New York City

Oslo, Norway, August 29, 2016 -- Photocure ASA hosted

on August 25 an educational event in New York aimed at

institutional investors and analysts, which focused on

the treatment of bladder cancer. At the event, key

opinion leaders (KOLs) from the New York

Presbyterian / Columbia Hospital, University of

Chicago, University of Texas Southwestern Medical

Center presented details on the diagnosis, treatment

and management of bladder cancer; gave an update on

the new American Urological Association / Society of

Urologic Oncology guidelines, and addressed progress

being made in the evolving field of genomics in

guiding treatment and the future direction of bladder

cancer management. During the event, physicians also

highlighted the role of Photocure's Blue Light

Cystoscopy with Cysview®, in the detection and

management of bladder cancer.

Kjetil Hestdal, President and CEO of Photocure

commented, "We would like to thank participants for

joining us at this informative event. We are

encouraged by the progress we are seeing with Blue

Light Cystoscopy with Cysview in the US marketplace

and are committed to making this important product

accessible to patients and physicians in this market."

The event was recorded and presentations can be found

at:

Link video: https://vimeo.com/180277493

Link presentation slides:

http://hugin.info/131151/R/2037762/759325.pdf

Cancer of the Urinary Bladder

Dr. Gary Steinberg; Bruce & Beth White Family

Professor of Surgery & Vice Chairman of Urology &

Director Urologic Oncology, University of Chicago

Genomic Landscape of Bladder Cancer

Dr. Yair Lotan; Professor, Chief Urologic Oncology,

Holder of the Helen J. & Robert Strauss Professorship,

Univ. of Texas Southwestern Medical Center

Risk Stratification and Guidelines for Management of

NMIBC

Dr. James McKiernan; John K. Lattimer Professor &

Chairman Dept. of Urology, College of Surgeons &

Urologist-in-Chief at NY Presbyterian Columbia

Hospital & Vice Chair, AUA Guidelines Committee

About Bladder Cancer

Bladder cancer is the fifth most common cancer in men

with more than 330,000 new cases annually and more

than 130,000 die of the disease1. It has a high

recurrence rate with an average of 61% in one year and

78% over five years, making the lifetime costs of

managing bladder cancer one of the highest amongst all

cancers. It is a costly, potentially progressive

disease for which patients have to undergo multiple

cystoscopies because of the high risk of recurrence. A

recent paper on the economic burden of bladder cancer

across the European Union estimates that bladder

cancer cost the EU 4.9 billion Euro in 20122. There is

an urgent need to improve both the diagnosis and the

management of bladder cancer for the benefit of

patients and healthcare systems alike.

Bladder cancer is classified into two types, non-

muscle invasive bladder cancer (NMIBC) and muscle-

invasive bladder cancer (MIBC), depending on the depth

of invasion in the bladder wall. NMIBC is still in the

inner layer of cells. These cancers are the most

common (75%) of all bladder cancer cases and in-clude

the subtypes Ta, carcinoma in situ (CIS) and T1

lesions. MIBC is when the cancer has grown into deeper

layers of the bladder wall. These cancers, including

subtypes T2, T3 and T4, are more likely to spread and

are harder to treat.

About Hexvix®/Cysview®

Hexvix®/Cysview® (hexaminolevulinate hydro-chloride)

is an innovative breakthrough technology in the

diagnosis and management of non-muscle-invasive

bladder cancer. It is designed to selectively target

malignant cells in the bladder and induce fluorescence

during a cystoscopic procedure using a blue light

enabled cystoscope. Using Hexvix®/Cysview® as an

adjunct to standard white light cystoscopy enables the

urologist to better detect and remove lesions, leading

to a reduced risk of recurrence.

Hexvix® is the tradename in Europe, Cysview® in U.S.

and Canada. Hexvix® is marketed and sold by Photocure

in the Nordic countries and in the US with the trade

name Cysview®. Photocure has a strategic partnership

with Ipsen for the commercialization of Hexvix in

Europe, excluding the Nordic region. Please refer to

https://www.photocure.com/Partnering-with-

Photocure/Our-partners for further information on our

commercial partners.

About Photocure ASA

Photocure, headquartered in Oslo, Norway, is a

specialty pharmaceutical company and world leader in

photodynamic technology. Based on our unique

proprietary Photocure Technology® platform, Photocure

develops and commercializes highly selective and

effective solutions within disease areas with high-

unmet medical need, such as bladder cancer, HPV and

precancerous cervical lesions, and skin conditions.

Our aim is to provide solutions, which can improve

health outcomes for patients worldwide. Photocure is

listed on the Oslo Stock Exchange (OSE: PHO).

Information about Photocure is available at

www.photocure.com.

Company contacts:

Kjetil Hestdal

President and CEO

Tel: +47 913 19 535

Email: kh@photcure.no

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

Investor relations:

Trout International LLC

Lauren Williams

Tel: +44 20 3780 4972

Email: lwilliams@troutgroup.com

References

1. Globocan. Incidence/mortality by population.

Available at:

http://globocan.iarc.fr/Pages/bar_pop_sel.aspx

(accessed March 2015)

2. Leal et al, Eur Urol 2016; 69: 438-447